Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer ("DURIPANC")Watch the "What This Means" segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that AIM CEO ...

OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral ...

OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s antiviral priority development pipeline. AIM has engaged Amarex Clinical Research (“Amarex”), its Clinical Research Organization (“CRO”), with the application and eventual management of a follow-up Investigational New Drug (“IND”) application for the study of a potential ...

OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company's antiviral priority development pipeline. AIM has engaged Amarex Clinical Research ("Amarex"), its Clinical Research Organization ("CRO"), with the application and eventual management of a follow-up Investigational New Drug ("IND") application for the study of a potential avian inf ...

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently OCALA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintato ...

OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final Clinical Study Results for the "Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions" ("AMP-518") was posted yesterday to ClinicalTrials.gov (See: NCT05592418). CEO Thomas K. Equels stated: "The results of AMP-518 support AIM's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of f ...

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response, offering potential therapeutic benefits for people with ME/CFS or Post-COVID chronic fatigue OCALA, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today offered commentary on a new article ...

AIM ImmunoTech Inc. (AIM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Ind ...

– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by the National Cancer Institute, AstraZeneca and Merck OCALA, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) ...

Company Overview - Plantible, founded in 2018, has developed a vertically integrated manufacturing platform to produce Rubi Protein™ from Lemna (duckweed), a plant-based protein that mimics the quality, taste, and texture of animal-based proteins and replaces synthetic emulsifiers and binders [1][5][6] - CH4 Global aims to reduce methane emissions in cattle by up to 90% using its flagship product, Methane Tamer™, a feed additive leveraging Asparagopsis seaweed [6][10][12] Industry Impact - Plantible's Rubi Protein™ addresses the food industry's need for cleaner, healthier, and allergen-friendly alternatives to unsustainable ingredients [1] - CH4 Global's Methane Tamer™ reduces methane emissions from cattle, a significant contributor to climate change, while improving feed efficiency and cattle growth or milk production [2][10][12] Strategic Investments - Chipotle's Cultivate Next venture fund has made minority investments in Plantible and CH4 Global to support their missions and align with Chipotle's goal of cultivating a better world [4][7][8] - The investment in CH4 Global will help scale production of Methane Tamer™ to meet global demand, targeting the world's 1.5 billion cattle [11][12] Technological Advancements - Plantible's manufacturing technology leverages the aquatic growth of Lemna, minimizes fresh water usage through recirculation, and reduces carbon emissions due to its efficient growing process [1] - CH4 Global's Asparagopsis-based solution not only reduces methane emissions but also improves energy and nutrition absorption in cattle, enhancing growth and milk production efficiency [2][10] Market Expansion - Chipotle plans to operate 7,000 restaurants in North America, supported by investments in innovative companies like Plantible and CH4 Global through its Cultivate Next fund [4][8] - Plantible and CH4 Global are part of Chipotle's broader portfolio, which includes companies focused on sustainable and innovative food solutions [8][9]